AC
ACONW
Aclarion, Inc.
$0.0345
0.00%
$67.7K
No data for this timeframe.
Vol
Market Cap$67.7K
Cap SizeNano Cap
Inst. Holders2 funds
Inst. Value$17.00
Inst. Activity1 buys / 0 sells
SEC Reports1
Recent Activity
Apr 22, 2026
SEC
Aclarion, Inc. announced a $2.5 million share repurchase program authorized by its board, to be executed over the next 1
8-K — Impact 4/10
Inst.
BANK OF AMERICA CORP — ADD
437 shares ($13.00)
Inst.
BANK OF AMERICA CORP — ADD
337 shares ($12.00)
Jun 3, 2026
contract
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Gener
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BANK OF AMERICA CORP | $13.00 | ADD |
| UBS Group AG | $4.00 | DOUBLED |
2 institutional holders with $17.00 total value (557 shares) as of 2025-Q3. Top holders: BANK, UBS. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | 437 | $13.00 | 76.5% | ADD +29.7% |
| 2 | UBS Group AG | 120 | $4.00 | 23.5% | DOUBLED +324.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 337 | 437 | +29.7% | $13.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 237 | 337 | +42.2% | $12.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 258 | 1,095 | +324.4% | $34.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 58 | 258 | +344.8% | $5.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 55.3% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 105.9% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 78.3% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 90.4% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
contract
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Jun 1, 2026
fda
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune Biomarker Study
May 28, 2026
other
Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal
Aclarion Comments on Echo Lake Capital’s Letter and Unsolicited Proposal
May 7, 2026
other
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
May 6, 2026
other
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
May 5, 2026
fda
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
Apr 30, 2026
earnings
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
Apr 28, 2026
other
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
Apr 22, 2026
buyback
Aclarion Announces $2.5 Million Stock Repurchase Plan
Aclarion Announces $2.5 Million Stock Repurchase Plan
Apr 16, 2026
other
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
Apr 7, 2026
other
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
Mar 19, 2026
other
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
Mar 19, 2026
activist
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
Mar 17, 2026
other
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
Mar 12, 2026
other
Aclarion CEO Brent Ness to Attend LSI USA 2026
Aclarion CEO Brent Ness to Attend LSI USA 2026